Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.
Marchetti A, Milella M, Felicioni L, Cappuzzo F, Irtelli L, Del Grammastro M, Sciarrotta M, Malatesta S, Nuzzo C, Finocchiaro G, Perrucci B, Carlone D, Gelibter AJ, Ceribelli A, Mezzetti A, Iacobelli S, Cognetti F, Buttitta F. Marchetti A, et al. Among authors: irtelli l. Neoplasia. 2009 Oct;11(10):1084-92. doi: 10.1593/neo.09814. Neoplasia. 2009. PMID: 19794967 Free PMC article.
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment.
Buttitta F, Felicioni L, Lorito AD, Cortellini A, Irtelli L, Brocco D, Marino PD, Traisci D, D'Ostilio N, Paolo AD, Malorgio F, Assalone P, Felice SD, Fabbri F, Cianci G, Tursi M, Marchetti A. Buttitta F, et al. Among authors: irtelli l. Oncotarget. 2020 Mar 17;11(11):982-991. doi: 10.18632/oncotarget.27517. eCollection 2020 Mar 17. Oncotarget. 2020. PMID: 32215186 Free PMC article.
ROS1 Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm.
Marchetti A, Barberis M, Di Lorito A, Pace MV, Di Lisio C, Felicioni L, Guerini-Rocco E, Vingiani A, D'Antuono T, Liberatore M, Filice G, De Luca G, De Marinis F, Passaro A, Guetti L, Irtelli L, Crinò L, Mucilli F, Buttitta F. Marchetti A, et al. Among authors: irtelli l. JCO Precis Oncol. 2017 Nov;1:1-9. doi: 10.1200/PO.16.00010. JCO Precis Oncol. 2017. PMID: 35172481
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer.
Novello S, Torri V, Grohe C, Kurz S, Serke M, Wehler T, Meyer A, Ladage D, Geissler M, Colantonio I, Cauchi C, Stoelben E, Ceribelli A, Kropf-Sanchen C, Valmadre G, Borra G, Schena M, Morabito A, Santo A, Gregorc V, Chiari R, Reck M, Schmid-Bindert G, Folprecht G, Griesinger F, Follador A, Pedrazzoli P, Bearz A, Caffo O, Dickgreber NJ, Irtelli L, Wiest G, Monica V, Porcu L, Manegold C, Scagliotti GV. Novello S, et al. Among authors: irtelli l. Ann Oncol. 2022 Jan;33(1):57-66. doi: 10.1016/j.annonc.2021.09.017. Epub 2021 Oct 5. Ann Oncol. 2022. PMID: 34624497 Free article. Clinical Trial.
21 results